Literature DB >> 19811223

MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia.

Kais Hussein1, Katharina Theophile, Wiebke Dralle, Birgitt Wiese, Hans Kreipe, Oliver Bock.   

Abstract

In primary myelofibrosis (PMF) and essential thrombocythemia (ET) the megakaryocytic lineage characteristically shows aberrant proliferation and maturation in which the regulatory microRNA (miR) system might be involved. Laser-microdissected PMF and ET megakaryocytes were analysed with real-time polymerase chain reaction (PCR) low density arrays comprising 365 microRNAs. The highest megakaryocytic expression levels were observed for miR-223, which is known to be expressed also in granulopoiesis. Cluster analysis revealed a tendency of disease-specific megakaryocytic microRNA expression profiles indicating that a complex shift of microRNA expression appears to be the underlying defect. Increased accumulation of miR-146b was observed in cellular stage PMF (p = 0.0125) but not ET megakaryopoiesis. In conclusion, this is the first microRNA profiling of in situ-derived PMF, ET and normal megakaryocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811223     DOI: 10.1080/09537100903114537

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  20 in total

1.  MicroRNA expression in maturing murine megakaryocytes.

Authors:  Joanna B Opalinska; Alexey Bersenev; Zhe Zhang; Alec A Schmaier; John Choi; Yu Yao; Janine D'Souza; Wei Tong; Mitchell J Weiss
Journal:  Blood       Date:  2010-08-18       Impact factor: 22.113

Review 2.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  [Pathobiology of the microRNA system].

Authors:  K Hussein
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 4.  MicroRNAs in platelet production and activation.

Authors:  Leonard C Edelstein; Paul F Bray
Journal:  Blood       Date:  2011-03-01       Impact factor: 22.113

Review 5.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

6.  Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.

Authors:  Belinda B Guo; Richard J Allcock; Bob Mirzai; Jacques A Malherbe; Fizzah A Choudry; Mattia Frontini; Hun Chuah; James Liang; Simon E Kavanagh; Rebecca Howman; Willem H Ouwehand; Kathryn A Fuller; Wendy N Erber
Journal:  Am J Pathol       Date:  2017-05-11       Impact factor: 4.307

7.  Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes.

Authors:  Jennifer Keck-Wherley; Deepak Grover; Sharmistha Bhattacharyya; Xiufen Xu; Derek Holman; Eric D Lombardini; Ranjana Verma; Roopa Biswas; Zygmunt Galdzicki
Journal:  Dev Neurosci       Date:  2011-10-27       Impact factor: 2.984

8.  microRNA-22 promotes megakaryocyte differentiation through repression of its target, GFI1.

Authors:  Cary N Weiss; Keisuke Ito
Journal:  Blood Adv       Date:  2019-01-08

9.  miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.

Authors:  Ruggiero Norfo; Roberta Zini; Valentina Pennucci; Elisa Bianchi; Simona Salati; Paola Guglielmelli; Costanza Bogani; Tiziana Fanelli; Carmela Mannarelli; Vittorio Rosti; Daniela Pietra; Silvia Salmoiraghi; Andrea Bisognin; Samantha Ruberti; Sebastiano Rontauroli; Giorgia Sacchi; Zelia Prudente; Giovanni Barosi; Mario Cazzola; Alessandro Rambaldi; Stefania Bortoluzzi; Sergio Ferrari; Enrico Tagliafico; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Blood       Date:  2014-08-05       Impact factor: 22.113

10.  α-Hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors.

Authors:  Philipp W Raess; Michelle E Paessler; Adam Bagg; Mitchell J Weiss; John Kim Choi
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.